30 July 2013

US court rules Teva patent invalid

A US court has ruled that an Israeli company’s patent for a multiple sclerosis (MS) drug is invalid, paving the way for rivals to market a generic version.

In a ruling at the US Court of Appeals for the Federal Circuit on Friday, July 26, Teva Pharmaceuticals was told one of its patents protecting the Copaxone drug was invalid. The patent in question was due to expire in 2015; other patents at issue were upheld by the court, but these expire in 2014.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Amgen hit with lawsuit over its proposed Opdivo biosimilar

16 September 2026 BMS is stepping up its defence of its blockbuster cancer drug Opdivo as Amgen moves closer to the biosimilar market.

Pharma

Beyond the primary patent: How pharma can build competitive barriers

16 September 2026 A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.

Biotech

Australian biotech sues Grail over multi-cancer blood test

15 September 2026 Grail is facing a patent infringement lawsuit over its Galleri cancer detection test, as Clinical Genomics seeks to enforce its intellectual property while no longer being commercially operational.